Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels
- 5 May 1989
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 261 (17) , 2525-2530
- https://doi.org/10.1001/jama.261.17.2525
Abstract
Testosterone was administered transdermally to hypogonadal men under there protocols. In the first protocol, it was shown that peak levels of tetosterone were achieved three to eight hours after scrotal application of a transdermal therapeutic system containing 5, 10, or 15 mg of testosterone, and values at 22 hours were greater than 60% of peak values. In the second protocol, patients were treated with 10-mg systems for four weeks followed by 15-mg systems for eight weeks. Serum samples were obtained three to five hours after application of the transdermal therapeutic system. Testosterone increased from a pretreatment level (mean .+-. SE) of 1.5 .+-. 0.4 nmol/L to 15.2 .+-. 3.4 nmol/L at four weeks, 18.6 .+-. 3.3 nmol/L at eight weeks, and 17.3 .+-. 2.8 nmol/L at 12 weeks. The serum testosterone/dihydrotestosterone (DHT) ratio fell from 4.53 to 2.47 at four weeks and was similar at eight and 12 weeks, reflecting a greater rise in DHT with this route of treatment (normal testosterone/DHT ratio, 9/1 to 12/1). Eight patients were treated with the 15-mg systems for an additional year. Seven of the eight were compliant and maintained serum testosterone levels (at six time points from two to 12 months (mean .+-. SE]) ranging from 11.5 .+-. 1.2 to 44.9 .+-.2.4 nmol/L. It was possible to achieve physiological serum levels of testosterone by transdermal administration of testosterone in two thirds of our hypogonadal men.This publication has 28 references indexed in Scilit:
- Response of Rat Ventral Prostate to a New and Novel 5αa-Reductase InhibitorEndocrinology, 1981
- Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP)Steroids, 1981
- CLINICAL EFFICACY OF TESTOSTERONE UNDECANOATE IN MALE HYPOGONADISMClinical Endocrinology, 1981
- ANDROGEN REPLACEMENT WITH ORAL TESTOSTERONE UNDECANOATE IN HYPOGONADAL MEN: A DOUBLE BLIND CONTROLLED STUDYClinical Endocrinology, 1981
- Absorption, Metabolism, and Excretion of Oral Testosterone in Humans by Mass FragmentographyJournal of Clinical Endocrinology & Metabolism, 1980
- Treatment of Male Hypogonadism with Testosterone Enanthate*Journal of Clinical Endocrinology & Metabolism, 1980
- Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patientsJournal of Endocrinological Investigation, 1980
- Steroid 5α-Reductase Deficiency in a 65-Year-Old Male Pseudohermaphrodite: The Natural History, Ultrastructure of the Testes, and Evidence for Inherited Enzyme Heterogeneity*Journal of Clinical Endocrinology & Metabolism, 1980
- Long‐Term Study of Oral Testosterone Undecanoate in Hypogonadal MalesInternational Journal of Andrology, 1978
- Mean Plasma Concentration, Metabolic Clearance and Basal Plasma Production Rates of Testosterone in Normal Young Men and Women Using a Constant Infusion Procedure: Effect of Time of Day and Plasma Concentration on the Metabolic Clearance Rate of TestosteroneJournal of Clinical Endocrinology & Metabolism, 1967